<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="162">
  <stage>Registered</stage>
  <submitdate>10/08/2005</submitdate>
  <approvaldate>15/08/2005</approvaldate>
  <actrnumber>ACTRN12605000148673</actrnumber>
  <trial_identification>
    <studytitle>Beta-blockers and Airways Disease</studytitle>
    <scientifictitle>A prospective observational study of cardiology patients to estimate the prevalence of coexistant obstructive airways disease using spirometry, to document cardiologists' current prescribing practices with regard to beta-blocker medications and to measure both short and long term adverse beta-blocker effects in terms of spirometry, respiratory symptoms, exacerbation rates and hospital admissions.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive airways disease - COPD</healthcondition>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study intervention comprised an interviewer-administered questionnaire and measurement of spirometry. Specifically at time of enrolment, prior to hospital discharge, at 6 months and 12 months respiratory symptoms, measures of spirometry and bronchodilator response (using Salbutamol 5mg and Ipratropium bromide 0.5 mg combined via a nebuliser for assessment of bronchodilator response), exacerbation rates and hospital admission rates were recorded.</interventions>
    <comparator />
    <control />
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Estimation of prevalence of obstructive airways disease amongst the study population</outcome>
      <timepoint>At time of enrolment, prior to hospital discharge, at 6 months and 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Define cardiologists' prescription practices with regard to beta-blocker medications in patients with obstructive airways disease.</outcome>
      <timepoint>Measurements recorded at time of hospital admission and hospital discharge.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess for adverse repsiratory effects of beta-blocker use, over a year's duration, in terms of presence/severity of respiratory symptoms, exacerbations rates, hospital admissions and spirometry performance.</outcome>
      <timepoint>Timing of measurements as defined above under interventions, except for exacerations and hospital admission rates which were assessed at enrolment, at 6 months and at 12 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Acceptance for hospital admission under the cardiology unit of Royal Pince Alfred Hospital for assessment and treatment of an acute cardiac condition</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>4/04/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Belinda Cochrane</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital (Central Sydney Area Health Service Ethics Committee)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Belinda Cochrane</name>
      <address>1/10 Gow St.
Balmain NSW 2041</address>
      <phone>+61 403969332</phone>
      <fax />
      <email>bcochrane@ozemail.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Belinda Cochrane</name>
      <address>1/10 Gow St.
Balmain NSW 2041</address>
      <phone>+61 403969332</phone>
      <fax />
      <email>bcochrane@ozemail.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>